title: Bufalin induces cell cycle arrest and apoptosis in gallbladder carcinoma cells.
abstract: Bufalin, a major digoxin-like immunoreactive component of the Chinese medicine Chan Su, has been shown to exert a potential for anticancer activity against various human cancer cell lines in vitro. However, no detailed studies have so far been reported on its action on human gallbladder carcinoma cells. In this study, bufalin remarkably inhibited growth in human gallbladder cancer cells by decreasing cell proliferation, inducing cell cycle arrest and apoptosis in a dose-dependent manner. Bufalin also disrupted the mitochondrial membrane potential (ΔΨm) and regulated the expression of cell cycle and apoptosis regulatory molecules. Activation of caspase-9 and the subsequent activation of caspase-3 indicated that bufalin may be inducing mitochondria apoptosis pathways. Intraperitoneal injection of bufalin for 3 weeks significantly inhibited the growth of gallbladder carcinoma (GBC-SD) xenografts in athymic nude mice. Taken together, the results indicate that bufalin may be a potential agent for the treatment of gallbladder cancer.
authors.affiliation: Institute of Biliary Tract Disease, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, jianglin1987_jl@126.com.
authors.forename: Lin
authors.initials: L
authors.lastname: Jiang
authors.forename: Ming-Ning
authors.initials: MN
authors.lastname: Zhao
authors.forename: Tian-Yu
authors.initials: TY
authors.lastname: Liu
authors.forename: Xiang-Song
authors.initials: XS
authors.lastname: Wu
authors.forename: Hao
authors.initials: H
authors.lastname: Weng
authors.forename: Qian
authors.initials: Q
authors.lastname: Ding
authors.forename: Yi-Jun
authors.initials: YJ
authors.lastname: Shu
authors.forename: Run-Fa
authors.initials: RF
authors.lastname: Bao
authors.forename: Mao-Lan
authors.initials: ML
authors.lastname: Li
authors.forename: Jia-Sheng
authors.initials: JS
authors.lastname: Mu
authors.forename: Wen-Guang
authors.initials: WG
authors.lastname: Wu
authors.forename: Qi-Chen
authors.initials: QC
authors.lastname: Ding
authors.forename: Yang
authors.initials: Y
authors.lastname: Cao
authors.forename: Yun-Ping
authors.initials: YP
authors.lastname: Hu
authors.forename: Bai-Yong
authors.initials: BY
authors.lastname: Shen
authors.forename: Zhu-Jun
authors.initials: ZJ
authors.lastname: Tan
authors.forename: Ying-Bin
authors.initials: YB
authors.lastname: Liu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D002018:Bufanolides / Q000494:pharmacology*; D020169:Caspases / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D005706:Gallbladder Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008297:Male; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D051379:Mice; D008819:Mice, Nude; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D002018:Bufanolides; D020169:Caspases; C022777:bufalin
references.citation: Oncogene. 1999 Apr 15;18(15):2413-21
references.pmid: 10229192
references.citation: Cell. 1995 Apr 21;81(2):149-52
references.pmid: 7736567
references.citation: FEBS Lett. 2003 Jun 5;544(1-3):153-9
references.pmid: 12782307
references.citation: Oncogene. 1998 Feb 12;16(6):779-87
references.pmid: 9488042
references.citation: World J Gastroenterol. 2007 Jun 28;13(24):3374-9
references.pmid: 17659679
references.citation: Cytotechnology. 2010 Dec;62(6):573-83
references.pmid: 20963488
references.citation: Mol Hum Reprod. 2005 Nov;11(11):817-23
references.pmid: 16390854
references.citation: Int J Mol Med. 2008 May;21(5):637-43
references.pmid: 18425357
references.citation: Prostate. 2003 Feb 1;54(2):112-24
references.pmid: 12497584
references.citation: Phytochemistry. 1998 May;48(1):1-29
references.pmid: 9621450
references.citation: Dev Cell. 2009 Jan;16(1):21-34
references.pmid: 19154716
references.citation: Cancer Sci. 2008 Dec;99(12):2467-76
references.pmid: 19037992
references.citation: Toxicol In Vitro. 2007 Apr;21(3):343-54
references.pmid: 17052885
references.citation: Chin Med J (Engl). 2011 Dec;124(24):4236-44
references.pmid: 22340393
references.citation: Int J Mol Sci. 2012;13(2):2025-35
references.pmid: 22408435
references.citation: Science. 2000 Aug 18;289(5482):1150-1
references.pmid: 10970229
references.citation: Anticancer Drugs. 2009 Jan;20(1):59-64
references.pmid: 19343001
references.citation: Oncogene. 2001 Jun 7;20(26):3354-62
references.pmid: 11423986
references.citation: Nature. 2000 Oct 12;407(6805):770-6
references.pmid: 11048727
references.citation: Essays Biochem. 2010;47:99-114
references.pmid: 20533903
references.citation: Cancer Cell Int. 2013 Jun 26;13(1):64
references.pmid: 23802572
references.citation: Cancer Lett. 2009 Aug 18;281(1):71-81
references.pmid: 19299076
references.citation: Mol Cancer. 2009 Oct 01;8:81
references.pmid: 19796390
references.citation: Free Radic Biol Med. 2011 Oct 1;51(7):1365-75
references.pmid: 21763418
references.citation: Exp Cell Res. 2000 Apr 10;256(1):50-7
references.pmid: 10739651
references.citation: Annu Rev Biochem. 1999;68:383-424
references.pmid: 10872455
references.citation: Leuk Res. 1995 Aug;19(8):549-56
references.pmid: 7658701
references.citation: Med Arh. 2007;61(1):30-3
references.pmid: 17582972
references.citation: Cancer Sci. 2011 May;102(5):951-8
references.pmid: 21288283
references.citation: Biochem Soc Trans. 2004 Jun;32(Pt3):493-5
references.pmid: 15157169
references.citation: Biotechnol Lett. 2009 Apr;31(4):487-94
references.pmid: 19039527
references.citation: Cancer Res. 1997 Aug 1;57(15):3097-100
references.pmid: 9242431
references.citation: Nature. 1997 Jun 19;387(6635):773-6
references.pmid: 9194558
references.citation: Cancer. 2009 Nov 15;115(22):5309-18
references.pmid: 19701908